Tag Archives: Deals
Trust Issues: Dealing with Academia
Worried they might get taken for a ride, university tech transfer offices are beginning to hire ex-pharma and biotech personnel to help negotiate deals with industry.
On exiting a theater, writers are often astounded and dismayed by the film resulting from a screenplay they’ve sold to a producer. Punch-up writers have added corny jokes, directors have [...]
Posted in Biotech, Deals, IP, R&D, Strategy, Technology, leadership Also tagged academia, collaboration, partnerships, technology transfer 1 Comment
Deals Don't Need Science To Be A Success
Deals don’t need science to be a success
By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC
Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will best be [...]
Posted in Global, Guest Blog, Strategy Also tagged Genentech, integration, mergers. M&A, Pfizer 2 Comments
Is Sanofi Right to Bank on MS Drug?
Newswires have long been waiting for Sanofi-Aventis to officially announce its acquisition of US biotech company Genzyme, but what few analysts were expecting is just how much the transaction would hedge on one potentially controversial product. As the focus of Sanofi’s contingent value rights (CVR) approach, Genzyme’s multiple sclerosis treatment Lemtrada (also sold as Campath [...]
Posted in Safety, Strategy, pricing Also tagged Genzyme, Lemtrada, MS, Multiple Sclerosis, Sanofi-Aventis 1 Comment
MedImmune Bets Its Fate on “Biobetters”
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market.
MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
Posted in Biotech, Deals, Global, R&D, Strategy Also tagged AstraZeneca, biobetters, biosimilars, MedImmune, R&D, Strategy 1 Comment

GSK: A Rebuffed Suitor for the Moment